The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...

The company believes Chinese authorities are probing allegations that two current and two former employees had illegally ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca Plc is increasingly looking to the United States for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drug maker’s share price ...

AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...